Response to Zhou and Shan: Interpreting long‐term response to rituximab in immune thrombocytopenia
HemaSphere · 2026-10 · 10 (10)
DOI: 10.1002/hem3.70520 ↗Kurz gefasst
Editorial in der Zeitschrift HemaSphere, online erschienen am 27.10.2026. Verfasst von Galina Tsykunova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hemato-Oncology Østfold Hospital Grålum Norway. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Hemato-Oncology Østfold Hospital Grålum Norway.
- Institute of Clinical Medicine University of Oslo Oslo Norway.
- Department of Hematology Haukeland University Hospital Bergen Norway.
- Aarhus University Hospital Aarhus Denmark.
- Department of Clinical Medicine Aarhus University Aarhus Denmark.
- Department of Hematology Oslo University Hospital Oslo Norway.
ORCID-Profile: Galina Tsykunova, Henrik Frederiksen, Christian Fynbo Christiansen, Marie Linder, Waleed Ghanima
Zitieren
APA
Tsykunova, G., Kristiansen, E. B., Tvedt, T. H. A., Frederiksen, H., Christiansen, C. F., Linder, M., Bahmanyar, S., & Ghanima, W. (2026). Response to Zhou and Shan: Interpreting long‐term response to rituximab in immune thrombocytopenia. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70520
Vancouver
Tsykunova G, Kristiansen EB, Tvedt THA, Frederiksen H, Christiansen CF, Linder M, et al. Response to Zhou and Shan: Interpreting long‐term response to rituximab in immune thrombocytopenia. HemaSphere. 2026;10(10). doi:10.1002/hem3.70520
BibTeX
@article{Tsykunova2026,
author = {Tsykunova, Galina and Kristiansen, Eskild Bendix and Tvedt, Tor Henrik Anderson and Frederiksen, Henrik and Christiansen, Christian Fynbo and Linder, Marie and Bahmanyar, Shahram and Ghanima, Waleed},
title = {Response to Zhou and Shan: Interpreting long‐term response to rituximab in immune thrombocytopenia},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {10},
doi = {10.1002/hem3.70520}
}
EUVIMED